Answers are grounded in this paper and cite their sources.
Lipid nanoparticles (LNPs) are widely used for nucleic acid delivery, but current kit-based methods of measuring encapsulation efficiency quantify only total RNA and cannot distinguish between multiple nucleic acid cargos within co-formulated LNPs. This limitation complicates formulation characterization, dose normalization, reproducibility, and therapeutic predictability. To address this challenge, we developed LEGEND (LNP Encapsulation by Gel Electrophoresis and Nucleic Acid Densitometry), a simple gel-based assay that enables independent quantification of multiple nucleic acids in co-loaded LNP formulations. Using mCherry mRNA and eGFP siRNA as model cargos, we evaluated SM-102 and DLin-MC3-DMA LNPs containing varying siRNA/mRNA ratios. LEGEND separated and quantified individual nucleic acids based on size, revealing that experimentally encapsulated siRNA/mRNA ratios frequently differed from intended formulation ratios. Furthermore, encapsulation preferences varied between ionizable lipids, with SM-102 favoring mRNA encapsulation and DLin-MC3-DMA favoring siRNA encapsulation. Dose-normalized transfection studies in reporter cells demonstrated that these differences significantly influenced gene silencing and transgene expression outcomes. Overall, LEGEND provides a simple, accessible, and robust method for quantifying individual nucleic acid cargos in multi-nucleic acid co-formulated LNPs, enabling improved formulation characterization, quality control, and development of next-generation nucleic acid therapeutics.
No takes yet. Share an insight, caveat, or question.
Bisht et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: